Real world experiences: Pirfenidone is well tolerated in patients with idiopathic pulmonary fibrosis

Respiratory Medicine

Volumn 108, Issue 1, 2014, Pages 224-226

  Chaudhuri, Nazia ^a   Duck, Annette ^a   Frank, Rebecca ^a   Holme, Jayne ^a   Leonard, Colm ^a  

^a WYTHENSHAWE HOSPITAL   (United Kingdom)

Author keywords

Idiopathic pulmonary fibrosis; Interstitial lung disease; Treatment

Indexed keywords

ACETYLCYSTEINE; PIRFENIDONE; PREDNISOLONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL NURSE SPECIALIST; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; GASTROINTESTINAL SYMPTOM; HUMAN; LIVER DYSFUNCTION; LUNG DIFFUSION CAPACITY; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OXYGEN THERAPY; PATIENT COMPLIANCE; PATIENT EDUCATION; PNEUMOTHORAX; PRESCRIPTION; PRIORITY JOURNAL; RASH; TREATMENT DURATION; VERY ELDERLY;

IDIOPATHIC PULMONARY FIBROSIS; INTERSTITIAL LUNG DISEASE; TREATMENT;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PYRIDONES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84893064990     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2013.11.005     Document Type: Article

References (2)

1. P. Noble, C. Albera, W. Bradford, U. Costabel, M.K. Glassberg, D. Kardatzke, and CAPACITY Study Group et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials Lancet 377 2011 1760 1769
2. G. Raghu, H.R. Collard, J.J. Egan, F.J. Martinez, J. Behr, K.K. Brown, and ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management Am J Respir Crit Care Med 183 6 2011 788 824